{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T01:19:59Z","timestamp":1772500799663,"version":"3.50.1"},"reference-count":132,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.revmed.2018.02.017","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T22:00:12Z","timestamp":1520546412000},"page":"699-710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Uv\u00e9ite m\u00e9dicamenteuse et effets ind\u00e9sirables des m\u00e9dicaments en ophtalmologie"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-9180","authenticated-orcid":false,"given":"S.","family":"Trad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2018.02.017_bib0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.revmed.2018.02.017_bib0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0039-6257(97)00130-6","article-title":"Drug-induced uveitis","volume":"42","author":"Moorthy","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0015","first-page":"1429","article-title":"Systemic vasculitis following influenza vaccination: a report of three cases and literature review","volume":"20","author":"Mader","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0020","first-page":"273","article-title":"Rifampin-induced antibodies","volume":"4","author":"Worlledge","year":"1976","journal-title":"Chemotherapy"},{"key":"10.1016\/j.revmed.2018.02.017_bib0025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/ciq112","article-title":"Development of cytomegalovirus (CMV) immune recovery uveitis is associated with Th17\u00a0cell depletion and poor systemic CMV-specific T cell responses","volume":"52","author":"Hartigan-O\u2019Connor","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2018.02.017_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/jop.1994.10.217","article-title":"Relevance of drug-melanin interactions to ocular pharmacology and toxicology","volume":"10","author":"Salazar-Bookarman","year":"1994","journal-title":"J Ocular Pharmacol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0002-9394(14)73031-4","article-title":"Aseptic meningitis and iridocyclitis related to ibuprofen","volume":"117","author":"Kaplan","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00002030-199005000-00009","article-title":"Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia\/arthritis","volume":"4","author":"Siegal","year":"1990","journal-title":"AIDS"},{"key":"10.1016\/j.revmed.2018.02.017_bib0045","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJM199402103300616","article-title":"Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol","volume":"330","author":"Shafran","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.02.017_bib0050","doi-asserted-by":"crossref","first-page":"510","DOI":"10.7326\/0003-4819-121-7-199410010-00006","article-title":"Uveitis associated with rifabutin prophylaxis","volume":"121","author":"Havlir","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2018.02.017_bib0055","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJM199405053301816","article-title":"Rifabutin prophylaxis and uveitis","volume":"330","author":"Fuller","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.02.017_bib0060","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0002-9394(14)72550-4","article-title":"Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection","volume":"118","author":"Jacobs","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0065","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1056\/NEJM199403243301218","article-title":"Rifabutin and uveitis","volume":"330","author":"Frank","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.02.017_bib0070","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/clinids\/21.3.594","article-title":"Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease","volume":"21","author":"Griffith","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2018.02.017_bib0075","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12348-012-0059-9","article-title":"Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia","volume":"2","author":"Smith","year":"2012","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.revmed.2018.02.017_bib0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0002-9394(98)00310-9","article-title":"Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia","volume":"127","author":"Smith","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0085","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/eye.2000.85","article-title":"Rifabutin-induced uveitis with inflammatory vitreous infiltrate","volume":"14","author":"Khan","year":"2000","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.revmed.2018.02.017_bib0090","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jac\/49.2.421","article-title":"Rifabutin-induced cystoid macular oedema","volume":"49","author":"Vaudaux","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.revmed.2018.02.017_bib0095","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0161-6420(00)00586-8","article-title":"Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals","volume":"108","author":"Bhagat","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2018.02.017_bib0100","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0161-6420(98)94019-2","article-title":"Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis","volume":"105","author":"Akler","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2018.02.017_bib0105","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/bjo.83.10.1153","article-title":"Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis","volume":"83","author":"Ambati","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/eye.1999.89","article-title":"Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS","volume":"13","author":"Bainbridge","year":"1999","journal-title":"Eye"},{"key":"10.1016\/j.revmed.2018.02.017_bib0115","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0420.1997.tb00783.x","article-title":"Bilateral anterior uveitis and retinal haemorrhages after administration of trimethoprim","volume":"75","author":"Kristinsson","year":"1997","journal-title":"Acta Ophthalmol Scand"},{"issue":"1","key":"10.1016\/j.revmed.2018.02.017_bib0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archopht.1991.01080010069035","article-title":"Systemic sulfonamides as a cause of bilateral, anterior uveitis","volume":"109","author":"Tilden","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/ICB.0000000000000028","article-title":"Retinal hemorrhages and intermediate uveitis in a patient with drug reaction with eosinophilia and systemic symptoms syndrome: a case report","volume":"8","author":"Colon","year":"2014","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.revmed.2018.02.017_bib0130","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1517\/17425255.2012.708337","article-title":"Ocular toxicity from systemically administered xenobiotics","volume":"8","author":"Gokulgandhi","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0135","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1542\/peds.76.6.989","article-title":"Diffuse retinopathy following measles, mumps, and rubella vaccination","volume":"76","author":"Marshall","year":"1985","journal-title":"Pediatrics"},{"key":"10.1016\/j.revmed.2018.02.017_bib0140","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0002-9394(78)90304-5","article-title":"Optic neuritis complicating measles, mumps, and rubella vaccination","volume":"86","author":"Kazarian","year":"1978","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0145","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/A:1006396906378","article-title":"Retinopathy following measles, mumps, and rubella vaccination in an immuno-incompetent girl","volume":"22","author":"Schuil","year":"1998","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0150","first-page":"564","article-title":"Arthritis and iritis after BCG therapy for bladder cancer","volume":"21","author":"Price","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0155","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0181-5512(06)73809-8","article-title":"Pan-uv\u00e9ite dans les suites d\u2019instillations intrav\u00e9sicales de BCG (Bacille de Calmette et Gu\u00e9rin)","volume":"29","author":"Jacob","year":"2006","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0160","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.ophtha.2009.05.021","article-title":"Uveitis in a patient treated with Bacille-Calmette-Gu\u00e9rin: possible antigenic mimicry of mycobacterial and retinal antigens","volume":"116","author":"Garip","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.revmed.2018.02.017_bib0165","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3928\/01913913-20080701-15","article-title":"Chronic anterior uveitis following bacille Calmette-Gu\u00e9rin vaccination: molecular mimicry in action?","volume":"45","author":"Spratt","year":"2008","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.revmed.2018.02.017_bib0170","article-title":"Uveitis","volume":"288(23)","author":"Nussenblatt","year":"1989"},{"key":"10.1016\/j.revmed.2018.02.017_bib0175","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/BF00167874","article-title":"Tuberculin skin-test-induced uveitis in the absence of tuberculosis","volume":"229","author":"Burgoyne","year":"1991","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0180","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0002-9394(14)73484-1","article-title":"Tuberculin-triggered panuveitis in a patient recently treated for active pulmonary tuberculosis","volume":"116","author":"Lish","year":"1993","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0185","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates. A comparative review","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Saf"},{"key":"10.1016\/j.revmed.2018.02.017_bib0190","first-page":"93","article-title":"Preclinical toxicology of bisphosphonates","volume":"57S","author":"Mondelo","year":"1997","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.revmed.2018.02.017_bib0195","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/bjophthalmol-2013-303355","article-title":"Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human cultured retinal pigment epithelial cells","volume":"97","author":"Or","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0200","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0140-6736(93)93029-Z","article-title":"Bisphosphonates and iritis","volume":"341","author":"Siris","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2018.02.017_bib0205","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0002-9394(14)72902-2","article-title":"Pamidronate disodium and possible ocular adverse drug reactions","volume":"118","author":"Marcarol","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9394(02)01840-8","article-title":"Scleritis and other ocular side effects associated with pamidronate disodium","volume":"135","author":"Fraunfelder","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0215","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jbmr.1783","article-title":"Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database","volume":"28","author":"Pazianas","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.revmed.2018.02.017_bib0220","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/ard.62.4.378","article-title":"Clodronate induced uveitis","volume":"62","author":"Fietta","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2018.02.017_bib0225","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/bjo.79.2.150","article-title":"Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa","volume":"79","author":"Hayasaka","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0230","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/BF02347624","article-title":"Development of Sj\u00f6gren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C","volume":"31","author":"Unoki","year":"1996","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0235","first-page":"309","article-title":"Retinal complications during interferon therapy for chronic hepatitis C","volume":"91","author":"Kawano","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0240","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/bjo.85.10.1171","article-title":"Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin","volume":"85","author":"Jain","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0245","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.3748\/wjg.v12.i23.3756","article-title":"Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C","volume":"12","author":"Okuse","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0250","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/bjo.2004.043968","article-title":"Is screening for interferon retinopathy in hepatitis C justified?","volume":"88","author":"Cuthbertson","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0255","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000326747","article-title":"Serous retinal detachments complicating interferon-\u03b1 and ribavirin treatment in patients with hepatitis C","volume":"2","author":"Modorati","year":"2011","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0260","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.2169\/internalmedicine.51.7771","article-title":"New-onset type 1\u00a0diabetes mellitus and anti-aquaporin-4\u00a0antibody positive optic neuritis associated with type 1\u00a0interferon therapy for chronic hepatitis C","volume":"51","author":"Kawazoe","year":"2012","journal-title":"Intern Med"},{"key":"10.1016\/j.revmed.2018.02.017_bib0265","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2169\/internalmedicine.47.1401","article-title":"Optic neuritis caused by interferon-beta administration","volume":"47","author":"Okuma","year":"2008","journal-title":"Intern Med"},{"key":"10.1016\/j.revmed.2018.02.017_bib0270","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/bjo.87.7.925","article-title":"Does etanercept induce uveitis?","volume":"87","author":"Reddy","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0275","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","article-title":"Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease","volume":"45","author":"Smith","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2018.02.017_bib0280","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2018.02.017_bib0285","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/ncprheum0225","article-title":"Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis","volume":"2","author":"Monnet","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0290","first-page":"2911","article-title":"The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis","volume":"34","author":"Kasner","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.revmed.2018.02.017_bib0295","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.22613","article-title":"Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the biologics in pediatric rheumatology registry","volume":"67","author":"Foeldvari","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2018.02.017_bib0300","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ophtha.2012.12.040","article-title":"Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis","volume":"120","author":"Zarbin","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2018.02.017_bib0305","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"Engl J Med"},{"key":"10.1016\/j.revmed.2018.02.017_bib0310","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.icu.0000143688.45232.15","article-title":"Drug-induced corneal complications","volume":"15","author":"Hollander","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0315","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12016-015-8469-8","article-title":"A critical review of the effects of hydroxychloroquine and chloroquine on the eye","volume":"49","author":"Costedoat-Chalumeau","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0320","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2018.02.017_bib0325","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016\u00a0revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2018.02.017_bib0330","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/OPTH.S14257","article-title":"Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the \u201cflying saucer\u201d sign)","volume":"4","author":"Chen","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0335","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/archophthalmol.2010.321","article-title":"Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy","volume":"129","author":"Michaelides","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0340","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ophtha.2014.07.018","article-title":"Pericentral retinopathy and racial differences in hydroxychloroquine toxicity","volume":"122","author":"Melles","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2018.02.017_bib0345","first-page":"621952","article-title":"Crystalline-like keratopathy after intravenous immunoglobulin therapy with incomplete Kawasaki disease: case report and literature review","volume":"2013","author":"Erdem","year":"2013","journal-title":"Case Rep Ophthalmol Med"},{"key":"10.1016\/j.revmed.2018.02.017_bib0350","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/eye.1996.30","article-title":"Vortex keratopathy associated with ibuprofen therapy","volume":"10","author":"Fitt","year":"1996","journal-title":"Eye (Lond)"},{"issue":"5","key":"10.1016\/j.revmed.2018.02.017_bib0355","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/0002-9394(68)92796-7","article-title":"Indomethacin, reduced retinal sensitivity, and corneal deposits","volume":"66","author":"Burns","year":"1968","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0360","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0002-9394(14)77969-3","article-title":"Keratopathy associated with the use of naproxen","volume":"99","author":"Szmyd","year":"1985","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0365","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/IAE.0000000000000242","article-title":"Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies","volume":"34","author":"Liu","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.revmed.2018.02.017_bib0370","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.ophtha.2012.03.002","article-title":"Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5\u00a0cases","volume":"119","author":"Saint-Jean","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2018.02.017_bib0375","first-page":"1167","article-title":"Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review","volume":"21","author":"Borkar","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.revmed.2018.02.017_bib0380","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.ophtha.2012.12.025","article-title":"Erlotinib-related corneal melting","volume":"120","author":"Chow","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2018.02.017_bib0385","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.eye.6701630","article-title":"Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (\u2018Iressa\u2019, ZD1839) in phase I and II clinical trials","volume":"19","author":"Tullo","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.revmed.2018.02.017_bib0390","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/ICO.0b013e318064584a","article-title":"Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature","volume":"26","author":"Zhang","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.revmed.2018.02.017_bib0395","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000444047","article-title":"Anterior uveitis caused by ocular side effects of afatinib: a case report","volume":"7","author":"Todokoro","year":"2016","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0400","first-page":"224","article-title":"Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer","volume":"6","author":"Dranko","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.revmed.2018.02.017_bib0405","doi-asserted-by":"crossref","first-page":"e1226","DOI":"10.1097\/MJT.0000000000000189","article-title":"Trichomegaly induced by cetuximab: case series and review the literature","volume":"23","author":"Koksal","year":"2016","journal-title":"Am J Ther"},{"key":"10.1016\/j.revmed.2018.02.017_bib0410","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/ICO.0b013e318166f483","article-title":"Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody)","volume":"27","author":"Foerster","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.revmed.2018.02.017_bib0415","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/0284186X.2011.555781","article-title":"Bilateral macular ischemia and severe visual loss following trastuzumab therapy","volume":"50","author":"Saleh","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0420","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ceo.12500","article-title":"Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization","volume":"43","author":"Kaya","year":"2015","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0425","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/ICO.0b013e3181922146","article-title":"Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2\u00a0therapy (vandetanib) for anaplastic astrocytoma","volume":"28","author":"Yeh","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.revmed.2018.02.017_bib0430","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/ICO.0b013e31823f8b9c","article-title":"Inhibition of corneal neovascularization in rats by systemic administration of sorafenib","volume":"31","author":"Seo","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.revmed.2018.02.017_bib0435","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/02713683.2011.635916","article-title":"In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate","volume":"37","author":"Dib","year":"2012","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.revmed.2018.02.017_bib0440","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/02713683.2013.833629","article-title":"Cytotoxic properties of sunitinib and sorafenib on human corneal epithelial cells","volume":"39","author":"Bayyoud","year":"2014","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.revmed.2018.02.017_bib0445","first-page":"108","article-title":"A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update","volume":"2","author":"Biswas","year":"2008","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.revmed.2018.02.017_bib0450","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/sj.eye.6701315","article-title":"Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec)","volume":"18","author":"Esmaeli","year":"2004","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.revmed.2018.02.017_bib0455","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/108076803322279426","article-title":"Ocular side-effects associated with imatinib mesylate (Gleevec)","volume":"19","author":"Fraunfelder","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.revmed.2018.02.017_bib0460","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.survophthal.2014.02.004","article-title":"Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy","volume":"59","author":"Kheir","year":"2014","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0465","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1097\/IOP.0000000000000140","article-title":"Cutaneous eyelid neoplasms as a toxicity of vemurafenib therapy","volume":"31","author":"Yin","year":"2015","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.revmed.2018.02.017_bib0470","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ajo.2014.07.003","article-title":"Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib","volume":"158","author":"Choe","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0475","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jamaophthalmol.2014.3024","article-title":"Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib","volume":"132","author":"Guedj","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273948.2016.1246666","article-title":"Uveitis and papillitis in the setting of dabrafenib and trametinib therapy for metastatic melanoma: a case report","volume":"28","author":"Lim","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2018.02.017_bib0485","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdu169","article-title":"Transient MEK inhibitor-associated retinopathy in metastatic melanoma","volume":"25","author":"Urner-Bloch","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0490","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/eye.2015.82","article-title":"MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity","volume":"29","author":"Duncan","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.revmed.2018.02.017_bib0495","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaophthalmol.2014.976","article-title":"Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer","volume":"132","author":"McCannel","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.revmed.2018.02.017_bib0500","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor\u00a0trametinib: a phase 1\u00a0dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0505","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.ajo.2015.07.035","article-title":"Ocular toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase kinase inhibitors: a case series","volume":"160","author":"Niro","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0510","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/ICB.0000000000000228","article-title":"Pimasertib and retinal detachments","volume":"10","author":"AlAli","year":"2016","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.revmed.2018.02.017_bib0515","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annder.2013.02.029","article-title":"Myosite orbitaire associ\u00e9e \u00e0 un traitement par ipilimumab","volume":"140","author":"Lecouflet","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0520","first-page":"140","article-title":"Ipilimumab-induced ocular and orbital inflammation--a case series and review of the literature","volume":"24","author":"Papavasileiou","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2018.02.017_bib0525","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CJI.0000000000000066","article-title":"Vogt-Koyanagi-Harada-like syndrome after CTLA-4\u00a0inhibition with ipilimumab for metastatic melanoma","volume":"38","author":"Crosson","year":"2015","journal-title":"J Immunother"},{"key":"10.1016\/j.revmed.2018.02.017_bib0530","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMicm1406501","article-title":"Images in clinical medicine. Amiodarone-induced vortex keratopathy","volume":"372","author":"Chan","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.02.017_bib0535","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/bjo.66.10.676","article-title":"Ocular changes resulting from therapy with amiodarone","volume":"66","author":"Ingram","year":"1982","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0540","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/eye.1999.217","article-title":"Ocular toxicity in low-dose tamoxifen: a prospective study","volume":"13","author":"Noureddin","year":"1999","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.revmed.2018.02.017_bib0545","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.survophthal.2005.11.001","article-title":"Update on ocular complications of systemic cancer chemotherapy","volume":"51","author":"Schmid","year":"2006","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0550","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0002-9394(81)90240-3","article-title":"Corneal toxicity with systemic cytarabine","volume":"91","author":"Hopen","year":"1981","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0555","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0404.1997.tb00280.x","article-title":"Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy","volume":"96","author":"Caraceni","year":"1997","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.revmed.2018.02.017_bib0560","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9394(98)00346-8","article-title":"Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy","volume":"127","author":"Lauer","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0565","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0002-9394(85)90676-2","article-title":"Adverse ocular reactions possibly associated with isotretinoin","volume":"100","author":"Fraunfelder","year":"1985","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0570","first-page":"429","article-title":"Ocular side effects of accutane therapy","volume":"9","author":"Lerman","year":"1992","journal-title":"Lens Eye Toxic Res"},{"key":"10.1016\/j.revmed.2018.02.017_bib0575","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1468-1331.2005.01025.x","article-title":"Ocular complications of neurological therapy","volume":"12","author":"Hadjikoutis","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0580","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(65)91524-2","article-title":"Oculocutaneous changes after years of high doses of chlorpromazine","volume":"1","author":"Cairns","year":"1965","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2018.02.017_bib0585","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/bjo.51.5.295","article-title":"Ocular melanosis with special reference to chlorpromazine","volume":"51","author":"Cameron","year":"1967","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0590","doi-asserted-by":"crossref","first-page":"e3360","DOI":"10.1097\/MD.0000000000003360","article-title":"A case report: anti-psychotic agents related ocular toxicity","volume":"95","author":"Choy","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2018.02.017_bib0595","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1212\/WNL.53.9.2082","article-title":"Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings","volume":"53","author":"Miller","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2018.02.017_bib0600","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bjo.2007.131789","article-title":"The effect of sildenafil on ocular blood flow","volume":"92","author":"Harris","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0605","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/IAE.0b013e31815ec2c8","article-title":"Central serous chorioretinopathy associated with sildenafil","volume":"28","author":"Fraunfelder","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.revmed.2018.02.017_bib0610","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ajo.2006.10.006","article-title":"Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5\u00a0inhibitors","volume":"143","author":"Margo","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0615","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcrs.2005.02.027","article-title":"Intraoperative floppy iris syndrome associated with tamsulosin","volume":"31","author":"Chang","year":"2005","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.revmed.2018.02.017_bib0620","first-page":"45","article-title":"Association between tamsulosin and intraoperative \u201cfloppy-iris\u201d syndrome","volume":"11","author":"Leibovici","year":"2009","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.revmed.2018.02.017_bib0625","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/eye.2016.122","article-title":"Medscape. Risk factors for intraoperative floppy iris syndrome: a prospective study","volume":"30","author":"Chatziralli","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.revmed.2018.02.017_bib0630","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0002-9394(03)00869-9","article-title":"Oculogyric crisis in patients taking cetirizine","volume":"137","author":"Fraunfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0635","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ajo.2004.04.072","article-title":"Ocular side effects from herbal medicines and nutritional supplements","volume":"138","author":"Fraunfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0640","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0002-9394(14)72216-0","article-title":"Vortex keratopathy associated with atovaquone","volume":"120","author":"Shah","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0645","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/archopht.1982.01030040746007","article-title":"Ocular toxicity associated with high-dose carmustine","volume":"100","author":"Shingleton","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0650","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/bjo.2006.091165","article-title":"A denileukin diftitox (Ontak) associated retinopathy?","volume":"90","author":"Ruddle","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.017_bib0655","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1212\/01.wnl.0000201313.24970.b8","article-title":"Linezolid-associated toxic optic neuropathy","volume":"66","author":"Rucker","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2018.02.017_bib0660","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/archopht.1994.01090150034012","article-title":"Crystalline retinopathy associated with long-term nitrofurantoin therapy","volume":"112","author":"Ibanez","year":"1994","journal-title":"Arch Ophthalmol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318300717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318300717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:39:49Z","timestamp":1759336789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866318300717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":132,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0248866318300717"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2018.02.017","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uv\u00e9ite m\u00e9dicamenteuse et effets ind\u00e9sirables des m\u00e9dicaments en ophtalmologie","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2018.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}